3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cyclophosphamide
2042
Radiotherapy
1859
Cisplatin
1825
Carboplatin
1533
Gemcitabine
1434
Paclitaxel
1289
Bevacizumab
1270
Docetaxel
1202
pembrolizumab
1199
Oxaliplatin
1160
Capecitabine
1144
Fluorouracil
1061
Dexamethasone
971
Rituximab
919
Nivolumab
908
Magnetic Resonance Spectroscopy
862
Etoposide
839
Doxorubicin
823
Drug Therapy
792
Radiosurgery
776
Irinotecan
775
Cytarabine
736
fludarabine
716
Leucovorin
676
Lenalidomide
608
fludarabine phosphate
564
Temozolomide
552
Radiation
541
Filgrastim
540
Cetuximab
537
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Interventional
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled
NCT02667925
2016-10-11
ISOTOVE
Centre Jean Perrin
Phase NA
Withdrawn